BioCentury
ARTICLE | Clinical News

Baricitinib: Additional Phase III data

July 20, 2015 7:00 AM UTC

Additional data from the double-blind, international Phase III RA-BEACON trial in 527 patients with moderately to severely active RA who had previously failed >=1 tumor necrosis factor (TNF) inhibito...